fund profile

MED III (“MED III”) is a vintage 2021 buyout fund dedicated to investing in healthcare industries in Europe and North America. The objective of the Fund is to build a diversified portfolio of companies operating across 7 healthcare sectors (“MedSegs”): Healthcare IT, MedTech, Pharma Services, Life Science Tools & Biologic Services, Biopharma Products, In Vitro Diagnostics, Consumer Health. The Fund intends to invest in established and profitable companies mainly in Europe, acquire majority and minority positions and develop companies through internationalization, innovation, professionalization and strategic developments.

As of 26th January 2023, MP II is an Article 8+ Fund. Article 8+ is an unofficial classification based on the European Sustainable Finance Disclosure Regulation (EU SFDR) but an emerging market practice following the latest definition of an Article 9 threshold for sustainable investments. ARCHIMED’s definition of sustainable investment relates to the attainment of SDG 3 and ARCHIMED’s Health Objectives. In practice, the majority (2/3) of the Fund has a sustainable investment goal as its objective and the remaining portion (1/3) is promoting social and environmental characteristics. Thus, MED III invests mostly in business activities that contribute towards improving health outcomes. The Fund seeks to generate a positive and measurable social impact through investments in healthcare companies developing innovative products, medical devices, or services to improve human, animal and environmental health.